Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study. (2019)

First Author: Reilmann R

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s1474-4422(18)30391-0

PubMed Identifier: 30563778

Publication URI: http://europepmc.org/abstract/MED/30563778

Type: Journal Article/Review

Volume: 18

Parent Publication: The Lancet. Neurology

Issue: 2

ISSN: 1474-4422